4.45
price up icon0.23%   0.010
 
loading
Schlusskurs vom Vortag:
$4.44
Offen:
$4.55
24-Stunden-Volumen:
286.07K
Relative Volume:
1.04
Marktkapitalisierung:
$141.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+12.37%
1M Leistung:
+12.66%
6M Leistung:
-77.85%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$4.45
$4.69
1-Wochen-Bereich:
Value
$3.93
$4.69
52-Wochen-Spanne:
Value
$2.88
$26.62

Bioage Labs Inc Stock (BIOA) Company Profile

Name
Firmenname
Bioage Labs Inc
Name
Telefon
510-806-1445
Name
Adresse
1445A SOUTH 50TH STREET, RICHMOND
Name
Mitarbeiter
64
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
BIOA's Discussions on Twitter

Vergleichen Sie BIOA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
BIOA
Bioage Labs Inc
4.45 141.97M 0 0 0 0.00
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
170.16 75.08B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.07 51.07B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.96 46.95B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.77 19.24B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
325.82 14.38B 2.99B 1.21B 1.13B 25.06

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-28 Eingeleitet William Blair Mkt Perform
2024-12-10 Herabstufung Morgan Stanley Overweight → Underweight
2024-12-09 Herabstufung Citigroup Buy → Neutral
2024-12-09 Herabstufung Jefferies Buy → Hold
2024-10-21 Eingeleitet Citigroup Buy
2024-10-21 Eingeleitet Jefferies Buy
2024-10-21 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten

pulisher
Jun 06, 2025

Lead Plaintiff Appointed in BioAge Labs Class Action — Here’s How You Can Recover Your Losses - TradingView

Jun 06, 2025
pulisher
Jun 04, 2025

BioAge Labs, Inc. Announces Updates on APJ Agonist Program Updates - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

BioAge Labs Updates Milestones for NLRP3 Program - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Bioage advances apelin receptor agonist program with option to Jikang’s nanobody - BioWorld MedTech

Jun 04, 2025
pulisher
Jun 04, 2025

BioAge deepens weight loss R&D with fresh apelin receptor push - The Pharma Letter

Jun 04, 2025
pulisher
Jun 03, 2025

BioAge Labs expands APJ agonist pipeline with biologic candidates - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

BioAge Labs Enters Option Agreement with JiKang Therapeutics to In-License Novel APJ Agonist Antibody and Expands Intellectual Property for Small Molecule APJ Agonists - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates - The Manila Times

Jun 03, 2025
pulisher
May 31, 2025

Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and BioAge Labs, Inc. (BIOA) - The Globe and Mail

May 31, 2025
pulisher
May 30, 2025

Bioage plans mid-year IND submission for BGE-102 for obesity - BioWorld MedTech

May 30, 2025
pulisher
May 30, 2025

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic - Pipelinereview

May 30, 2025
pulisher
May 30, 2025

BioAge advances obesity drug into clinical trials By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 29, 2025

BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 - Insider Monkey

May 29, 2025
pulisher
May 29, 2025

Jefferies maintains hold on BioAge Labs with $4 target By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Jefferies maintains hold on BioAge Labs with $4 target - Investing.com

May 29, 2025
pulisher
May 29, 2025

BioAge Labs, Inc. Completes IND-enabling Studies for BGE-102 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

BioAge advances obesity drug into clinical trials - Investing.com Australia

May 29, 2025
pulisher
May 29, 2025

BioAge Labs completes IND-enabling studies for BGE-102, a - GlobeNewswire

May 29, 2025
pulisher
May 27, 2025

BioAge Labs to Present at Upcoming Investor Conferences - The Manila Times

May 27, 2025
pulisher
May 27, 2025

BioAge Labs Announces Major Investor Presentations: Key Updates Expected at Global Healthcare Conferences - Stock Titan

May 27, 2025
pulisher
May 21, 2025

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Class Action Filed Against BioAge Labs, Inc. (BIOA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

May 21, 2025
pulisher
May 20, 2025

BioAge Leaders Touted Obesity Drug Before Safety Woes, Suit Says - Bloomberg Law News

May 20, 2025
pulisher
May 13, 2025

Invitation to presentation of BioArctic's first quarter report for JanuaryMarch 2025 on May 21 at 9.30 a.m. CET - Stock Titan

May 13, 2025
pulisher
May 12, 2025

Investors who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class ActionBIOA - ACCESS Newswire

May 12, 2025
pulisher
May 12, 2025

Cautious Outlook on BioAge Labs, Inc. Amid Program Setbacks and Financial Concerns - TipRanks

May 12, 2025
pulisher
May 11, 2025

Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

May 11, 2025
pulisher
May 11, 2025

Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

May 11, 2025
pulisher
May 11, 2025

Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc. (BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

May 11, 2025
pulisher
May 11, 2025

Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIOA - ACCESS Newswire

May 11, 2025
pulisher
May 10, 2025

Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA - ACCESS Newswire

May 10, 2025
pulisher
May 09, 2025

Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsBIOA - ACCESS Newswire

May 09, 2025
pulisher
May 08, 2025

BioAge Labs Advances Pipeline with Strategic Collaborations - TipRanks

May 08, 2025
pulisher
May 06, 2025

BioAge Labs, Inc Q1 Loss Narrows - Nasdaq

May 06, 2025
pulisher
May 06, 2025

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times

May 06, 2025
pulisher
May 06, 2025

With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest - Yahoo Finance

May 06, 2025
pulisher
May 01, 2025

BioAge Labs, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsBIOA - ACCESS Newswire

May 01, 2025
pulisher
May 01, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 01, 2025
pulisher
Apr 30, 2025

INVESTOR DEADLINE MONDAY: BioAge Labs, Inc. Investors with Subst - GuruFocus

Apr 30, 2025
pulisher
Apr 26, 2025

Investors who lost money on BioAge Labs, Inc. should contact Levi & Korsinsky about an ongoing investigationBIOA - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 25, 2025

BioAge Labs, Inc. Being Investigated on Behalf of BioAge Labs, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

Investors who hold shares of BioAge Labs, Inc. (NASDAQ: BIOA) - openPR.com

Apr 24, 2025
pulisher
Apr 24, 2025

Notice to Long-Term Shareholders of BioAge Labs, Inc. - GlobeNewswire

Apr 24, 2025
pulisher
Apr 22, 2025

Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings - Bluefield Daily Telegraph

Apr 22, 2025

Finanzdaten der Bioage Labs Inc-Aktie (BIOA)

Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$13.90
price up icon 3.50%
$8.71
price up icon 2.96%
drug_manufacturers_specialty_generic RGC
$685.85
price up icon 9.74%
$125.39
price up icon 0.63%
drug_manufacturers_specialty_generic RDY
$15.55
price up icon 0.13%
$325.82
price up icon 1.91%
Kapitalisierung:     |  Volumen (24h):